Advanced Soft Tissue Sarcoma
Conditions
Keywords
TRC105, CD105, Endoglin, Angiogenesis Inhibitor, STS, Soft Tissue Sarcoma, TKI, Tyrosine Kinase Inhibitor, Pazopanib, Votrient, Advanced Soft Tissue Sarcoma, Angiosarcoma
Brief summary
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma. Up to 30 patients will be treated. The purpose of the phase 2 portion is to estimate the PFS of patients with advanced soft tissue sarcoma by RECIST 1.1 and estimate ORR in a separate cohort of patients with angiosarcoma by RECIST 1.1. Up to 89 patients will be treated in phase 2, including two cohorts of up to 13 patients with angiosarcoma.
Detailed description
Pazopanib is an oral inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor VEGFR-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. Pazopanib is approved for the treatment of advanced soft tissue sarcoma, following progression on one prior systemic therapy, based on improved progression free survival. TRC105 is an antibody to CD105, an important angiogenic target on vascular endothelial cells that is distinct from VEGFR. TRC105 inhibits angiogenesis, tumor growth and metastases in preclinical models and complements the activity of bevacizumab and multi-kinase inhibitors that target the VEGFR. In a phase 1 study of advanced solid tumors, TRC105 therapy caused a global reduction in angiogenic biomarkers and reduced tumor burden at doses that were well-tolerated. In a phase 1b study, the combination of TRC105 and bevacizumab produced radiographic reductions in tumor volume in bevacizumab-refractory patients, and was well tolerated. TRC105 potentiates bevacizumab and VEGFR tyrosine kinases (VEGFR TKI) in preclinical models. By targeting a non-VEGF pathway that is upregulated following VEGF inhibition, TRC105 has the potential to complement VEGFR TKIs and could represent a major advance in cancer therapy. Together, the use of TRC105 with pazopanib may result in more effective angiogenesis inhibition and improved clinical efficacy over that seen with pazopanib alone.
Interventions
DRUGTRC105 and Pazopanib
Weekly TRC105 in combination with standard dose Pazopanib.
Sponsors
Tracon Pharmaceuticals Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed unresectable soft tissue sarcoma that has progressed following treatment with chemotherapy. Prior pazopanib is allowed if the drug was not discontinued for toxicity ( Phase 1b only) 2. Histologically confirmed metastatic soft tissue sarcoma that has progressed by RECIST following treatment with anthracycline chemotherapy. Patients may have received up to four lines of systemic therapy for metastatic disease and no more than two lines of combination treatment ( Phase 2 only) 3. Histologically confirmed locally advanced (e.g. unresectable) or metastatic angiosarcoma that has progressed following treatment with prior systemic therapy. Progression must be documented on or following the most recent systemic therapy. Prior pazopanib is allowed if the drug was not discontinued for toxicity (Phase 2 angiosarcoma cohorts only) 4. Measurable disease by RECIST 5. Age of 12 years or older (patient must weigh ≥ 40 kg) 6. ECOG performance status ≤ 1 7. Resolution of all acute adverse events resulting from prior cancer therapies to NCI CTCAE grade ≤ 1 or baseline (except alopecia or neuropathy) 8. Adequate organ function. 9. Willingness and ability to consent for self to participate in study 10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures 11. Available archival tumor specimen of the soft tissue sarcoma that meets inclusion criterion #1, #2 or #3
Exclusion criteria
1. Prior treatment with TRC105 2. Prior treatment with a VEGFR TKI (including pazopanib) (Phase 2 only) 3. Current treatment on another therapeutic clinical trial 4. Receipt of systemic anticancer therapy, including investigational agents, within 28 days of starting study treatment. 5. No major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; date of surgery (if applicable) or the anticipated need for a major surgical procedure within the next six months. 6. Patients who have received wide field radiotherapy ≤ 28 days or limited field radiation for palliation \< 14 days prior to cycle 1 day 1 or those patients who have not recovered adequately from side effects of such therapy 7. Uncontrolled chronic hypertension 8. Significant ascites or pericardial or pleural effusion 9. History of brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. 10. Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, PTCA or CABG within the past 6 months. Deep venous thrombosis within 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred. 11. Active bleeding or pathologic condition that carries a high risk of bleeding. Patients who have been uneventfully anti-coagulated with low molecular weight heparin are eligible. 12. Thrombolytic use (except to maintain i.v. catheters) within 10 days prior to first day of study therapy 13. Known active viral or nonviral hepatitis or cirrhosis 14. History of hemorrhage or hemoptysis within 3 months of starting study treatment 15. History of peptic ulcer within the past 3 months of treatment 16. History of gastrointestinal perforation or fistula in the past 6 months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved 17. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness 18. Receipt of a strong CYP3A4 inducer within 12 days prior to cycle 1 day 1 or a strong CYP3A4 inhibitor within 7 days prior to cycle 1 day 1. 19. Pregnancy or breastfeeding. Female patients must be surgically sterile (i.e.: hysterectomy) or be postmenopausal, or must agree to use effective contraception during the study and for 3 months following last dose of TRC105. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to first dose. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 3 months following last dose of TRC105. The definition of effective contraception will be based on the judgment of the Principal Investigator or a designated associate. 20. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose Limiting Toxicity (DLT) | 56 days | For DLT evaluation, severity (grade) was classified according to common terminology criteria for adverse events version 4.0 (CTCAE v4.0). DLTs were defined as grade 4 neutropenia persisting for ≥ 5 days, febrile neutropenia (grade 4 neutropenia with fever \> 38.5 ºC both sustained over a 24 hour period), neutropenic infection (grade ≥ 3 neutropenia with grade ≥ 3 infection), anemia ≥ grade 4, grade \> 4 thrombocytopenia or grade ≥ 3 thrombocytopenia and grade ≥ 3 hemorrhage, or grade 3 or 4 nonhematologic toxicity with the following exceptions: nausea, vomiting, or diarrhea for \<48 hours, asymptomatic electrolyte abnormalities that are corrected to grade 1 or better in \< 72 hours, or headache lasting less than 48 hours. |
| Progression Free Survival of Patients With Advanced Soft Tissue Sarcoma (Phase 1 and 2) | from screening to either disease progression or death | Number of patients with progression free survival, as defined as time from screening to either first disease progression or death from any cause per RECIST version 1.1 |
| Objective Response Rate in a Cohort of Patients With Angiosarcoma | 1.5 years | The best response according to RECIST 1.1 for each patient in the phase 2 angiosarcoma cohort with measurable disease and who received at least one dose of study drug will be listed by cohort and tumor type |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | 12 months | The best response (CR, PR, SD or PD according to RECIST 1.1) for each patient (phase 1 and phase 2) with measurable disease who received at least one dose of TRC105 study drug |
| Trough Concentrations of TRC105 (Phase 2) | 4, 6, 8, and 10 weeks | Trough serum TRC105 concentrations will be measured using validated ELISA methods. |
| Progression Free Survival in a Cohort of Patients With Angiosarcoma (Phase 2) | 26 months | Time from screening to either first disease progression or death from any cause per RECIST version 1.1 |
| Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | 32 months | Anti-product antibody concentrations will be measured using validated ELISA methods. Anti-product antibody concentrations will be evaluated in the context of pharmacokinetic parameters and AE profiles. |
| Number of Patients With and Without Expression of Endoglin on Sarcoma Tissue (Phase 1 and 2) | 12 months | Expression will be determined by immunohistochemistry for each patient who received at least one dose of TRC105 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 8 mg/kg TRC105 + Pazopanib 8 mg/kg of TRC105 in combination with standard dose pazopanib in patients with advanced soft tissue sarcoma. | 3 |
| 10 mg/kg TRC105 + Pazopanib 10 mg/kg of TRC105 in combination with standard dose pazopanib in patients with advanced soft tissue sarcoma. | 108 |
| Total | 111 |
Baseline characteristics
| Characteristic | Total | 8 mg/kg TRC105 + Pazopanib | 10 mg/kg TRC105 + Pazopanib |
|---|---|---|---|
| Age, Continuous | 58 years | 55 years | 58 years |
| ECOG Performance Status ECOG Grade 0 | 33 Participants | 2 Participants | 31 Participants |
| ECOG Performance Status ECOG Grade 1 | 78 Participants | 1 Participants | 77 Participants |
| ECOG Performance Status ECOG Grade 2 | 0 Participants | 0 Participants | 0 Participants |
| ECOG Performance Status ECOG Grade 3 | 0 Participants | 0 Participants | 0 Participants |
| ECOG Performance Status ECOG Grade 4 | 0 Participants | 0 Participants | 0 Participants |
| ECOG Performance Status ECOG Grade 5 | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 6 Participants | 0 Participants | 6 Participants |
| Race/Ethnicity, Customized Black or African American | 9 Participants | 1 Participants | 8 Participants |
| Race/Ethnicity, Customized Caucasian | 91 Participants | 2 Participants | 89 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 5 Participants | 0 Participants | 5 Participants |
| Region of Enrollment United States | 111 participants | 3 participants | 108 participants |
| Sex: Female, Male Female | 60 Participants | 1 Participants | 59 Participants |
| Sex: Female, Male Male | 51 Participants | 2 Participants | 49 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 9 / 106 |
| other Total, other adverse events | 3 / 3 | 106 / 106 |
| serious Total, serious adverse events | 0 / 3 | 9 / 106 |
Outcome results
Primary
Number of Participants With Dose Limiting Toxicity (DLT)
For DLT evaluation, severity (grade) was classified according to common terminology criteria for adverse events version 4.0 (CTCAE v4.0). DLTs were defined as grade 4 neutropenia persisting for ≥ 5 days, febrile neutropenia (grade 4 neutropenia with fever \> 38.5 ºC both sustained over a 24 hour period), neutropenic infection (grade ≥ 3 neutropenia with grade ≥ 3 infection), anemia ≥ grade 4, grade \> 4 thrombocytopenia or grade ≥ 3 thrombocytopenia and grade ≥ 3 hemorrhage, or grade 3 or 4 nonhematologic toxicity with the following exceptions: nausea, vomiting, or diarrhea for \<48 hours, asymptomatic electrolyte abnormalities that are corrected to grade 1 or better in \< 72 hours, or headache lasting less than 48 hours.
Time frame: 56 days
Population: All phase 1b patients who received at least a portion of a dose of TRC105
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TRC105 Plus Pazopanib | Number of Participants With Dose Limiting Toxicity (DLT) | Patients with DLT at 8 mg/kg | 0 Participants |
| TRC105 Plus Pazopanib | Number of Participants With Dose Limiting Toxicity (DLT) | Patients without DLT at 8 mg/kg | 3 Participants |
| TRC105 Plus Pazopanib | Number of Participants With Dose Limiting Toxicity (DLT) | Patients with DLT at 10 mg/kg | 1 Participants |
| TRC105 Plus Pazopanib | Number of Participants With Dose Limiting Toxicity (DLT) | Patients without DLT at 10 mg/kg | 22 Participants |
Primary
Objective Response Rate in a Cohort of Patients With Angiosarcoma
The best response according to RECIST 1.1 for each patient in the phase 2 angiosarcoma cohort with measurable disease and who received at least one dose of study drug will be listed by cohort and tumor type
Time frame: 1.5 years
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TRC105 Plus Pazopanib | Objective Response Rate in a Cohort of Patients With Angiosarcoma | Complete Response (CR) | 2 Participants |
| TRC105 Plus Pazopanib | Objective Response Rate in a Cohort of Patients With Angiosarcoma | Partial Response (PR) | 0 Participants |
| TRC105 Plus Pazopanib | Objective Response Rate in a Cohort of Patients With Angiosarcoma | Stable Disease (SD) | 3 Participants |
| TRC105 Plus Pazopanib | Objective Response Rate in a Cohort of Patients With Angiosarcoma | Progressive Disease (PD) | 0 Participants |
| TRC105 Plus Pazopanib | Objective Response Rate in a Cohort of Patients With Angiosarcoma | Not Evaluable | 0 Participants |
Primary
Progression Free Survival of Patients With Advanced Soft Tissue Sarcoma (Phase 1 and 2)
Number of patients with progression free survival, as defined as time from screening to either first disease progression or death from any cause per RECIST version 1.1
Time frame: from screening to either disease progression or death
Population: All patients with scans completed at baseline and at least 1 time point on study.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| TRC105 Plus Pazopanib | Progression Free Survival of Patients With Advanced Soft Tissue Sarcoma (Phase 1 and 2) | 5.06 months |
| 10 mg/kg TRC105 + Pazopanib | Progression Free Survival of Patients With Advanced Soft Tissue Sarcoma (Phase 1 and 2) | 3.45 months |
Secondary
Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2)
Anti-product antibody concentrations will be measured using validated ELISA methods. Anti-product antibody concentrations will be evaluated in the context of pharmacokinetic parameters and AE profiles.
Time frame: 32 months
Population: All patients who received at least a portion of a dose of TRC105 with immunogenicity samples collected at baseline and at least 1 time point on study
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TRC105 Plus Pazopanib | Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | Pt with treatment emergent ADA | 1 Participants |
| TRC105 Plus Pazopanib | Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | Pt without treatment emergent ADA | 2 Participants |
| 10 mg/kg TRC105 + Pazopanib | Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | Pt with treatment emergent ADA | 12 Participants |
| 10 mg/kg TRC105 + Pazopanib | Number of Patients With and Without Development of Immunogenicity Antibodies (Phase 1 and 2) | Pt without treatment emergent ADA | 67 Participants |
Secondary
Number of Patients With and Without Expression of Endoglin on Sarcoma Tissue (Phase 1 and 2)
Expression will be determined by immunohistochemistry for each patient who received at least one dose of TRC105
Time frame: 12 months
Population: All patients who received TRC105. Endoglin expression levels determined through archival tumor samples, which were drawn before dosing. Therefore dose levels combined.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TRC105 Plus Pazopanib | Number of Patients With and Without Expression of Endoglin on Sarcoma Tissue (Phase 1 and 2) | Tumor endoglin expression positive | 15 Participants |
| TRC105 Plus Pazopanib | Number of Patients With and Without Expression of Endoglin on Sarcoma Tissue (Phase 1 and 2) | Tumor endoglin expression negative | 51 Participants |
Secondary
Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1
The best response (CR, PR, SD or PD according to RECIST 1.1) for each patient (phase 1 and phase 2) with measurable disease who received at least one dose of TRC105 study drug
Time frame: 12 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TRC105 Plus Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Progressive Disease (PD) | 0 Participants |
| TRC105 Plus Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Complete Response (CR) | 0 Participants |
| TRC105 Plus Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Partial Response (PR) | 0 Participants |
| TRC105 Plus Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Stable Disease (SD) | 3 Participants |
| TRC105 Plus Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Not Evaluable | 0 Participants |
| 10 mg/kg TRC105 + Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Not Evaluable | 4 Participants |
| 10 mg/kg TRC105 + Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Stable Disease (SD) | 43 Participants |
| 10 mg/kg TRC105 + Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Complete Response (CR) | 3 Participants |
| 10 mg/kg TRC105 + Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Progressive Disease (PD) | 27 Participants |
| 10 mg/kg TRC105 + Pazopanib | Objective Response Rate in Patients With Advanced Soft Tissue Sarcoma by RECIST 1.1 | Partial Response (PR) | 1 Participants |
Secondary
Progression Free Survival in a Cohort of Patients With Angiosarcoma (Phase 2)
Time from screening to either first disease progression or death from any cause per RECIST version 1.1
Time frame: 26 months
| Arm | Measure | Value (MEAN) |
|---|---|---|
| TRC105 Plus Pazopanib | Progression Free Survival in a Cohort of Patients With Angiosarcoma (Phase 2) | 5.59 months |
Secondary
Trough Concentrations of TRC105 (Phase 2)
Trough serum TRC105 concentrations will be measured using validated ELISA methods.
Time frame: 4, 6, 8, and 10 weeks
Population: All patients who received at least a portion of a dose of TRC105 with PK samples collected at baseline and at least 1 time point on study
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| TRC105 Plus Pazopanib | Trough Concentrations of TRC105 (Phase 2) | Cycle 2 Day 1 (4 weeks) trough PK concentrations | 124 ug/mL |
| TRC105 Plus Pazopanib | Trough Concentrations of TRC105 (Phase 2) | Cycle 2 Day 15 (6 weeks) trough PK concentrations | 86 ug/mL |
| TRC105 Plus Pazopanib | Trough Concentrations of TRC105 (Phase 2) | Cycle 3 Day 1 (8 weeks) trough PK concentrations | 91 ug/mL |
| TRC105 Plus Pazopanib | Trough Concentrations of TRC105 (Phase 2) | Cycle 3 Day 15 (10 weeks) trough PK concentrations | 80 ug/mL |